P53 Immunolabeling in EUS ‐FNA Biopsy can Predict Low Resection Rate and Early Recurrence in Resectable or Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Therapy

ConclusionsPretreatment abnormal labeling of p53 in EUS-FNA specimen was associated with a lower resection rate and an early recurrence in R or BR PDAC cases.

Source: Journal of Hepato-Biliary-Pancreatic Sciences - November 30, 2022 Category: Gastroenterology Authors: Minoru Oshima, Keiichi Okano, Hideki Kamada, Hironobu Suto, Yasuhisa Ando, Emi Ibuki, Ryo Ishikawa, Tsutomu Masaki, Reiji Haba, Yasuyuki Suzuki Tags: ORIGINAL ARTICLE Source Type: research